Skripsi
RASIONALITAS TERAPI ANTIDIABETK ORAL PADA PENDERITA DIABETES MELITUS TIPE 2 DI RUMAH SAKIT PELABUHAN PALEMBANG PERIODE AGUSTUS 2010 - JULI 2011
Background: Diabetes Mellitus is the degenerative disease that's increased continuously its prevalence. Based on researchfrom Global Prevalence of Diabetes, Diabetes Care 2004, the DM patients in Indonesia around 8,4 million and fourth rank of world. Monotherapy or combination usage of Oral anti diabetic (OAD) frequently used to achieve optimal glycemic control. The purpose of the research to know the OAD usage rationality in DM type 2 patients in Rumah Sakit Pelabuhan Palembang from August 2010 to July 2011. METHODS: Drug utilization study has been conducted in Rumah Sakit Pelabuhan Palembang from November to December 2011. The sample with suspected type 2 diabetes was identified from the outpatients medical record over the period of August 2010 to July 2011. Data of 89 patients were collected and analyzed. The main analysis is based on descriptive statistical method, using SPSS. RESULTS: Based on 89 medical records, there are 52 (58.42%) females and 37 (41.57%) males. The interval ages D M type 2 patients are most often in age 50 to 59 years old. A total of 120 antidiabetic medications were prescribed. The usage of generic name is amounted 55 (45,83%), brand name 24 (20%), andpatent name 41 (34,17) . The usage of Sulfonilurea is 82 (68,33%) cases, Biguanid 34 (28.33%) and a-Glycosidase Inhibitor 4 (3.33%). The administered doses for 1 mg Glimepiride occurredin 10 (15.625%) cases, 2 mg 53 (81.25%) cases and 4 mg 2 (3.125%) cases; Glibenclamid doses, 1.25 mg occurred in 3 (18.75%) cases, 2.5 mg 10 (6.25%) cases, and 5 mg 3 (18.75%) cases; Gliclazide doses, 40 mg occurred in 2 (100%) cases; Metformin doses, 250 mg occurred in 2 (5.88%) cases, 500 mg 30 (88.24%) cases, and 850 mg 2 (5.88%) cases; Acarbose doses, 50 mg occurred in 4 (100%) cases. The frequency of Glimepiride usage which once a day is 45 (70.31%) cases, twice a day is 18 (28.13%) cases, and three times a day is 1 (1.56%) case; Glibeclamide usage which once a day is 2 (12.5%) cases, twice a day is 14 (87.5%) cases; Gliclazide usage which twice a day is 2 (100%) cases; Metformin usage which once a day is 7 (20.59%) cases, twice a day is 27 (79.41%>) cases; Acarbose usage which twice a day is 3 cases (75%), and three times a day is 1 case (25% ). The duration of administration of OAD for 7 day s occurred in 3 (3.37%) cases, 10 day 49 (55.06%) cases, and 14 days 37 (41.57%) cases. The usage of single dose of OAD occurred in 62 (69.66%) cases and combination dose occurred in 27 (30.34%) There are three type of interactions of OAD which are synergy occurred in 29 (24.97%) cases, potenciation occurred in 55 (47.01%>) cases, and antagonistic occurred ini 33 (28.2%) cases. CONCLUSION: There were irrationality in administered frequency of Glimepiride which was 19 (29.69%) cases, and in duration of administration of OAD which 52 (58.43%) cases, and also in interaction which has antagonistic interaction between OAD and the other drugs is 33(28.2%) cases.
Inventory Code | Barcode | Call Number | Location | Status |
---|---|---|---|---|
1207000205 | T82151 | T821512012 | Central Library (REFERENCES) | Available but not for loan - Not for Loan |
No other version available